BRIEF-Structure Therapeutics - Aleniglipron Shows Up To 16.2% Weight Loss Beyond 36 Weeks In Phase 2B Trial

Structure

Structure

GPCR

0.00

June 5 (Reuters) - Structure Therapeutics Inc GPCR.O:

  • STRUCTURE THERAPEUTICS - ALENIGLIPRON SHOWS UP TO 16.2% WEIGHT LOSS BEYOND 36 WEEKS IN PHASE 2B TRIAL

  • STRUCTURE THERAPEUTICS - PHASE 3 PROGRAM FOR ALENIGLIPRON TO INITIATE IN Q3 2026

  • STRUCTURE THERAPEUTICS - ALENIGLIPRON DEMONSTRATES 10.4% DISCONTINUATION RATE WITH FAVORABLE TOLERABILITY

Source text: ID:nGNXwbK7L

Further company coverage: GPCR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.